25+ Presentations from Top Pharma at Drug Discovery Chemistry Europe
DEL Case Studies
Thomas Franch, PhD, Executive Director, Research, Amgen
Molecular Glue Degraders & Stabilisers beyond Cereblon
Ryan Potts, PhD, Executive Director and Head, Induced Proximity Platform, Amgen, Inc.
Predicting Protein-Ligand Binding Modes in a Structure-Rich Environment
Marcel Verdonk, PhD, Senior Director, Computational Chemistry & Informatics, Astex Pharmaceuticals
X-Ray Crystallographic Fragment Screening for the Identification of Allosteric Binding Sites
David Twigg, PhD, Senior Research Associate, Chemistry, Astex Pharmaceuticals
Druggable Pockets in β-Glucocerebrosidase (GCase), a Parkinson's Disease Drug Target
Christopher Agnew, PhD, Project Lead, Astex Pharmaceuticals
Computational Approaches to Finding PPIs as Starting Points for Molecular Glue Projects
Sergio Martinez Cuesta, PhD, Associate Director in Bioinformatics, AstraZeneca
Discovery of a Novel Class of Brain-Penetrant Inhibitors of KRASG12C
Doyle Cassar, PhD, Senior Research Scientist, Medicinal Chemistry, AstraZeneca
Leveraging Biophysical Tools via Novel Assay Configurations to Accelerate Lead Generation
Stefan Geschwindner, PhD, Director, AstraZeneca R&D Gothenburg
Utilising Affinity Screening Approaches to Accelerate Hit Discovery
Rachel Moore, PhD, Associate Principal Scientist, High Throughput Screening, AstraZeneca R&D
Tackling KRAS with Complementary Modalities—Discovery of PROTACs and Small Molecule Inhibitors
Tobias Wunberg, PhD, Director Medicinal Chemistry, Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co. KG
Antiviral PPI Inhibitors: Invention of the HIV-1 Maturation Inhibitor VH3739937 (VH-937)
Alicia Regueiro-Ren, PhD, Scientific Senior Director, Medicinal Chemistry, Bristol Myers Squibb Co.
Development of Orally Bioavailable RAS-Inhibitory Peptide Guided by Drug-Like Criteria
Atsushi Ohta, PhD, Head of Modality Technology Department, Chugai Pharmaceutical Co., Ltd.
Small Molecule Lead-Finding Trends: Commonalities and Differences across Independent Research Organisations
Wolfgang Haap, Distinguished Scientist, Medicinal Chemistry, F Hoffmann La Roche AG
A Disulfide Constrained Peptide Platform to Identify Binders of the E3 Ubiquitin Ligase ZNRF3
Xinxin Gao, PhD, Principal Scientific Manager, Peptide Therapeutics, Genentech, Inc.
From Selection to Lead-Development of DEL Compounds
Westley F. Tear, PhD, Investigator, ELT Drug Design & Selection, GSK
Many Roads towards Novel Glue Discovery
Markus Queisser, PhD, Scientific Director, Protein Degradation, GSK
Lessons Learned at GSK to Identify and Optimise PROTACs
Maxime Rouah, PhD, Investigator, Medicinal Chemistry, GSK
Enabling and Testing Generative and Predictive AI in the Drug Discovery Pipeline
Jose Carlos Gómez-Tamayo, Scientist, Johnson & Johnson Innovative Medicine
Discovery and Development of MK-0616: Macrocyclic Oral PCSK9 Inhibitor
Abbas M. Walji, PhD, Senior Director, Discovery Chemistry Modalities, Merck & Co., Inc.
Probing Biology with High-Quality Molecular Degraders
Ingo Hartung, PhD, Head, Medicinal Chemistry & Drug Design, Merck KGaA
Discovery of the First Non-Covalent WRN Helicase Inhibitor
Jacques Hamon, PhD, Associate Director, Oncology Biochemistry, Novartis Institutes for Biomedical Research
Identification and Optimisation of a Novel Series of KRAS G12C Inhibitors Leading to the Discovery of JDQ443 and Beyond
Simona Cotesta, PhD, Director Data Science, Novartis Biomedical Research
Discovery of HRO761, a Novel, First-in-Class Clinical Stage WRN Inhibitor by Structure and Property-Based Design Using ab initio Conformational Analysis
Henrik Moebitz, Director, CADD, Global Discovery Chemistry, Novartis Biomedical Research
Discovery of Cellular Active PDHK1/2 Inhibitor: Iterative Screening and FBDD Approaches
Ge Zou, PhD, Principal Scientist, Medicinal Chemistry, Roche
γ-Secretase Modulators (GSMs)
Rosa Maria Rodriguez Sarmiento, PhD, Expert Scientist & Project Lead, Medicinal Chemistry, Roche Pharma
AI-Assisted Clustering and Selection of Macrocyclic Peptides from mRNA Display Screening
Emzo De Los Santos, PhD, Lead Scientist, ML NBE, UCB Pharma
* As of 20 July. Please see individual agenda pages for most up-to-date agenda.